astragaloside a has been researched along with Diabetes Mellitus, Type 2 in 9 studies
*Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, L; Meng, Q; Yan, D; Yang, CJ; Zhang, L; Zhang, X; Zhang, Y | 1 |
| Chen, G; Dong, X; Kuang, B; Li, B; Li, X; Li, Z; Wu, Y; Zhang, L | 1 |
| Cao, SS; Feng, L; Han, CJ; Liu, JP; Shi, LL; Shi, Y; Wang, B; Wang, X; Zhang, RH; Zhang, YH | 1 |
| Chen, D; Guo, X; Xu, S; Ye, R; Yin, T; Zhang, Y | 1 |
| Wang, H; Wang, J; Zhang, H; Zhang, Z; Zhu, Y | 1 |
| Dong, X; Han, Y; Li, W; Li, Y; Su, Y; Zhang, J; Zhang, Y; Zhu, Y | 1 |
| Chen, Q; Ju, Y; Li, W; Ma, K; Su, Y | 1 |
| Gao, Y; Tian, N; Wang, T; Wang, X; Wu, B; Xu, J; Zhang, N; Zhu, Z | 1 |
| Chen, Q; Ji, T; Ju, Y; Li, W; Ma, K; Su, Y; Wang, Z | 1 |
9 other study(ies) available for astragaloside a and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
[Effect of intestinal flora changes on pharmacokinetics of astragaloside Ⅳ].
Topics: Animals; Chromatography, High Pressure Liquid; Chromatography, Liquid; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Saponins; Tandem Mass Spectrometry; Triterpenes | 2021 |
Astragaloside IV attenuates myocardial dysfunction in diabetic cardiomyopathy rats through downregulation of CD36-mediated ferroptosis.
Topics: Animals; CD36 Antigens; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Down-Regulation; Ferroptosis; Lipids; Myocytes, Cardiac; Rats | 2023 |
Astragaloside IV-mediated inhibition of oxidative stress by upregulation of ghrelin in type 2 diabetes-induced cognitive impairment.
Topics: AMP-Activated Protein Kinases; Animals; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Ghrelin; Insulin Resistance; Oxidative Stress; Rats; Superoxide Dismutase-1; Up-Regulation | 2023 |
Astragaloside IV Regulates Insulin Resistance and Inflammatory Response of Adipocytes
Topics: Adipocytes; Diabetes Mellitus, Type 2; Glucose; Humans; Insulin Resistance; Interleukin-6; MicroRNAs; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Tumor Necrosis Factor-alpha | 2023 |
Astragaloside IV alleviates myocardial damage induced by type 2 diabetes via improving energy metabolism.
Topics: Animals; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Energy Metabolism; Male; Muscle Proteins; Myocardium; Rats; Rats, Sprague-Dawley; Saponins; Triterpenes | 2019 |
Astragaloside IV alleviates liver injury in type 2 diabetes due to promotion of AMPK/mTOR‑mediated autophagy.
Topics: AMP-Activated Protein Kinases; Animals; Astragalus propinquus; Autophagy; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucose; Homeostasis; Insulin Resistance; Liver; Male; Oxidative Stress; Quality of Life; Rats; Rats, Sprague-Dawley; Saponins; Streptozocin; TOR Serine-Threonine Kinases; Triterpenes | 2021 |
Astragalosides IV protected the renal tubular epithelial cells from free fatty acids-induced injury by reducing oxidative stress and apoptosis.
Topics: Apoptosis; Caspase 3; Cell Line; Diabetes Mellitus, Type 2; Epithelial Cells; Fatty Acids, Nonesterified; Glucose; Humans; Kidney Tubules; Oxidation-Reduction; Oxidative Stress; Protective Agents; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Saponins; Signal Transduction; Triterpenes | 2018 |
Astragaloside IV represses high glucose-induced mesangial cells activation by enhancing autophagy via SIRT1 deacetylation of NF-κB p65 subunit.
Topics: Acetylation; Animals; Autophagy; Cell Proliferation; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Glucose; Male; Mesangial Cells; Mice; Mice, Inbred C57BL; Saponins; Sirtuin 1; Structure-Activity Relationship; Transcription Factor RelA; Triterpenes | 2018 |
Protective effects of Astragaloside IV on endoplasmic reticulum stress-induced renal tubular epithelial cells apoptosis in type 2 diabetic nephropathy rats.
Topics: Activating Transcription Factor 4; Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Down-Regulation; eIF-2 Kinase; Endoplasmic Reticulum Stress; Epithelial Cells; Male; Rats; Rats, Sprague-Dawley; Saponins; Streptozocin; Transcription Factor CHOP; Triterpenes | 2019 |